There was an improvement in disease-free interval for patients in the bevacizumab group compared with those in the observation group ( HR @ , @ % CI @-@ @ , p = @ ) , but no significant difference between groups for distant-metastasis-free interval ( HR @ , @ % CI @-@ @ , p = @ ) .